Endpoints Media Bias

---

Sanofi flies new flag for meningitis awareness

Exactly one year in advance of the Paris 2024 Paralympic Games, Sanofi is flying a new flag to raise awareness of the still significant and serious problems of meningitis. The newly-designed, first-ever meningitis flag is meant as a symbol of the fight, commitment to end the disease and the determination of the meningitis community and people who have survived the disease, said Sanofi executive VP, vaccines, Thomas Triomphe. Thomas Triomphe Three Team Sanofi Paralympians for the upcoming Paris games — Ellie Challis from Great Britain, Davide Morana from Italy and Théo Cuin from France — are supporting the global campaign and were also involved in creating it.

Endpoints     Aug 28, 2023

BridgeBio's ATTR-CM drug acoramidis bests placebo in detailed data, bolstering plans for NDA

Bridge­Bio pre­sent­ed de­tailed pos­i­tive da­ta from its Phase III tri­al of aco­ramidis in pa­tients with transthyretin amy­loid car­diomy­opa­thy (AT­TR-CM) at the Eu­ro­pean So­ci­ety of Car­di­ol­o­gy Con­gress this week­end, bol­ster­ing its plans to seek FDA ap­proval this year.

Endpoints     Aug 28, 2023

BlueRock, Bayer's stem cell division, details promising, early results from Parkinson's study

A treatment that aims to restore the damaged and dying brain cells that cause uncontrollable movements in Parkinson’s disease is showing promising, albeit early, signs of being safe and effective. BlueRock Therapeutics, Bayer’s stem cell therapy subsidiary, on Monday revealed the first detailed look at the results from a Phase I trial of bemdaneprocel, a therapy made from lab-grown neurons surgically implanted in the brains of 12 patients with Parkinson’s. In an interview ahead of the company’s presentation at a Parkinson’s meeting in Copenhagen, BlueRock CEO Seth Ettenberg told News that the company hoped to answer three questions with the study: Would the cells engraft after implanting them in a patient’s brain?

Endpoints     Aug 28, 2023

Riding the wave on latest obesity buyout; Slack interview with anti-aging researcher; Two new IRA lawsuits; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points?

Endpoints     Aug 26, 2023

Neumora boards IPO train as second PhIII biotech to file Nasdaq ... - Endpoints News

tech

The large­ly dor­mant biotech IPO mar­ket start­ed siz­zling Fri­day, with two Phase III drug de­vel­op­ers send­ing in their pitch­es for Nas­daq de­buts this fall.

Endpoints     Aug 25, 2023

CDMO BioPharma Solutions names new CEO ahead of proposed $4B+ sale

Bax­ter’s CD­MO arm, Bio­Phar­ma So­lu­tions, has an­nounced a new CEO will take the reins fol­low­ing its pro­posed sale to pri­vate eq­ui­ty com­pa­ny Ad­vent In­ter­na­tion­al and in­vest­ment out­fit War­burg Pin­cus for $4 bil­lion.

Endpoints     Aug 25, 2023

Pharma enters 'age of uncertainty' amid challenges from IRA, FTC ... - Endpoints News

It’s been a de­mand­ing year for the phar­ma in­dus­try. There’s a more ag­gres­sive FTC, a chang­ing FDA, tough mar­ket con­di­tions, and a le­gal fight over the drug pric­ing pro­vi­sions in the In­fla­tion Re­duc­tion Act.

Endpoints     Aug 25, 2023

FDA publishes Oncopeptides' withdrawal appeal for Swedish ... - Endpoints News

tech

On­copep­tides’ ap­peal to the FDA’s with­draw­al pro­pos­al for the blood can­cer drug Pepax­to has been made pub­lic, shed­ding new light on the see­saw­ing that’s been go­ing on at the Swedish biotech.

Endpoints     Aug 25, 2023

HHS, drugmakers roll out plans for fall Covid, flu and RSV three-vaccine season

Last fall’s virus triple­dem­ic is giv­ing way to this year’s three-vac­cine sea­son. And the De­part­ment of Health and Hu­man Ser­vices says it is pulling out all the stops to make sure as many Amer­i­cans who need them get Covid-19, flu and RSV im­mu­niza­tions this fall.

Endpoints     Aug 25, 2023

Merck kick-starts PhIII cholesterol trials for its oral PCSK9; Baxter recalls 13,000+ vials of chemotherapy

Endpoints     Aug 25, 2023

Merck and Eisai to stop Keytruda plus Lenvima trial in head and neck cancer after disappointing interim results

Mer­ck and Ei­sai an­nounced Fri­day morn­ing that they plan to close a Phase III study of the com­bi­na­tion of Keytru­da and Ei­sai’s ty­ro­sine ki­nase in­hibitor Lenvi­ma in head and neck squa­mous cell car­ci­no­ma.

Endpoints     Aug 25, 2023

RayzeBio pencils in IPO plans, foreshadowing expected post-Labor Day bump in biotech listings

tech

A Phase III-stage ra­dio­phar­ma­ceu­ti­cals biotech has filed to go pub­lic a lit­tle over a week be­fore bankers and in­dus­try watch­ers ex­pect a slight post-La­bor Day bump in biotech IPO pitch­es.

Endpoints     Aug 25, 2023